TGen, Dell expand pediatric cancer fight to Europe and Middle East

(The Translational Genomics Research Institute) Dell today announced its extended partnership with the Translational Genomics Research Institute (TGen) to help clinical researchers and doctors globally expand the reach and impact of the world's first FDA-approved precision medicine trial for pediatric cancer. The renewed commitment includes an additional $3 million Dell grant to support continued collaboration with TGen and support the Neuroblastoma and Medulloblastoma Translational Research Consortium's expanded pediatric cancer clinical trials in EMEA, starting with sites in France and Lebanon.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news